US5676977A

Extracted document text. Layout, formulas and symbols may not survive extraction; consult the preserved PDF for the original presentation.

Text extraction covers 4 pages, including 4 transcribed by optical character recognition.

Page 1

United States Patent 1

MO ON A YR
US005676977A

t11) Patent Number: 5,676,977

Antelman [45] Date of Patent: Oct. 14, 1997
[54] METHOD OF CURING AIDS WITH 5,336,499 8/1994 Antelman 424/405
TETRASILVER TETROXIDE MOLECULAR 5,571,520 11/1996 Antelman 424/618

[75]
(73]

21)
[22]

[63]

51]
[52]
58]

[56]

CRYSTAL DEVICES
Inventor: Marvin S. Antelman, Rehovot, Israel

Assignee: Antelman Technologies Ltd.,
Providence, RI.

Appl. No.: 658,955
Filed: May 31, 1996

Related U.S. Application Data

Continuation-in-part of Ser. No. 310,859, Sep. 22, 1994,
abandoned.

Int. CL ..... w- AGIK 33/38
US. CL. .. 424/618; 514/495
Field of Search 424/618; 514/495

References Cited
U.S. PATENT DOCUMENTS

4,415,565 11/1983 Wysor
4,915,955 4/1990 Gomori
4,952,411 8/1990 Fox, Jr. et al.
5,073,382 12/1991 Antelman ..
5,078,902 1/1992 Antelman ..
5,089,275 2/1992 Antelman ..
5211,855 5/1993 Antelman ..
5,223,149 6/1993 Antelman ..

424/618
424/616
424/618
424/604
424/618
424/602
424/618
424/618

OTHER PUBLICATIONS

“Is The AIDS Virus A Science Fiction?” by Peter H. Dues-
berg and Bryan J. Ellison. Policy Review, Summer 1990, pp.
40-51.

Primary Examiner—Amy Hulina
Attomey, Agent, or Firm—Salter & Michaelson

[57] ABSTRACT

The diamagnetic semiconducting molecular crystal tetrasil-
ver tetroxide (Ag,O,) is utilized for destroying the AIDS
virus, destroying AIDS synergistic pathogens and immunity
suppressing moieties (ISM) in humans.

A single intravenous injection of the devices is all that is
required for efficacy at levels of about 40 PPM of human
blood. The device molecular crystal contains two mono and
two trivalent silver ions capable of “firing” electrons capable
of electrocuting the AIDS virus, pathogens and ISM. When
administered into the bloodstream, the device electrons will
be triggered by pathogens, a proliferating virus and ISM,
and when fired will simultaneously trigger a redox chelation
mechanism resulting in divalent silver moieties which che-
Jate and bind active sites of the entities destroying them. The
devices are completely non-toxic. However, they put stress
on the liver causing hepatomegaly, but there is no loss of
liver function.

3 Claims, No Drawings

Page 2

5,676,977

1

METHOD OF CURING AIDS WITH
TETRASILVER TETROXIDE MOLECULAR
CRYSTAL DEVICES

This application is a continuation-in-part of patent appli-
cation Ser. No. 08/310,859 filed Sep. 22, 1994, now aban-
doned.

BACKGROUND OF THE INVENTION

The present invention relates to the employment of
molecular crystals as anti-AIDS devices, but more particu-
larly to the molecular crystal semiconductor tetrasilver
tetroxide Ag,O, which has two monovalent and two triva-
lent silver ions per molecule, and which through this struc-
tural configuration enables intermolecular electron transfer
capable of killing viruses and binding them to the resulting
silver entity so that a single intravenous injection will
completely obliterate acquired immune deficiency syndrome
(AIDS) in humans. Furthermore, said devices are capable of
Killing pathogens and purging the bloodstream of immune
suppressing moieties (ISM) whether or not created by the
AIDS virus (HIV); so as to restore the immune system.

The present invention is based on concepts previously
elucidated in applicant’s U.S. Pat. No. 5,336,499 which
discloses the destruction and inhibition of bacteria, algae
and the AIDS virus in nutrient life supporting systems by
using said silver oxide devices. Example 3 of said patent
discloses that 18 PPM of said crystal devices could totally
suppress the AIDS virus (page 6, line 5). Subsequent to the
filing of the aforementioned patent, further testing revealed
complete 100% destruction of the AIDS virus in vitro at 20
PPM, and the fact that said devices were harmless when
ingested and inhaled, being non-toxic.

Encouraged by these evaluations and successes, applicant
obtained permission to evaluate the crystals in vitro against
murine acquired immune deficiency syndrome (MAIDS).
Only one facility in the State of Israel is licensed for these
evaluations, namely, the Kaplan Hospital in Rehovot, Israel,
which is affiliated with the Hebrew University-Hadassah
Medical School where said evaluations were done.

The initial evaluations entailed experimenting with vari-
ous silver moieties cited in applicant’s aforementioned
patent, concentrations, non-reactive buffers and modes of
administration. After about 18 months of judicious efforts
and initial failures, success was finally achieved in destroy-
ing the MAIDS virus in C57BL mice with a single intrave-
nous injection. The results of this test program comprise
Example 5 of U.S. Pat. No. 5,336,499. After success with
mice, the inventor was able to test the efficacy of said
devices on two select etiological groups of terminal AIDS
patients in a clinic in Tegucigalpa, Honduras, Central
America.

The AIDS patients comprised the etiological subgroups,
Candidiasis and Wasting Syndrome. Current indicator dis-
eases for diagnosing AIDS which have been expanded by
the CDC, fall into the following five major categories with
the approximate percent distribution among AIDS patients:

51%
19%
13%
11%

6%

This invention concerns itself with the treatment and cure
of candidiasis and wasting syndrome AIDS patients with

35

55

2

Tetrasil*. These two groups account for approximately one
third of AIDS cases.
*Trademark of Holipharm Corporation (of Israel) for AgsO,

Stedman’s Medical Dictionary (Williams & Wilken’s
26th Ed., 1995) defines wasting syndrome “as a condition of
10% weight loss in conjunction with diarrhea or fever . . .
Associated with AIDS (p. 1744).”

OBJECTS OF THE INVENTION

The main object of the invention is to provide for a
molecular scale device of a single tetrasilver tetroxide
crystalline molecule capable of restoring the immunity of
AIDS afflicted humans of the two AIDS etiological
subgroups, candidiasis and wasting syndrome.

Another object of the invention is to provide for immunity
restoration in said AIDS afflicted humans through a single
injection.

Another object of this invention is to destroy ISM in
humans manifesting AIDS diseases of said AIDS etiological
subgroups irrespective as to whether said ISM was HIV
induced, since it is known that humans may manifest AIDS
and still be HIV negative, and thus restore the immune
system in said humans.

Another object of this invention is to destroy the AIDS
virus when present in the systems of said AIDS afflicted
humans.

SUMMARY OF THE INVENTION

This invention relates to a molecular scale device not only
capable of destroying the AIDS virus, but of purging the
human bloodstream of pathogens and restoring immunity to
AIDS patients of the candidiasis and wasting syndrome
categories. Said molecular device consists of a single crystal
of tetrasilver tetroxide (Ag,O.,). The crystal lattice of this
molecule has a unique structure since it is a diamagnetic
semiconducting crystal containing two mono and two triva-
lent silver ions, which in effect are capable of “firing”
electrons under certain conditions which will destroy AIDS
viruses, other pathogens and immune suppressing moieties
(ISM), not only through the electrocution mode, but also by
a binding process which occurs simultaneously with electron
firing, namely, binding and chelation of divalent silver, ie.,
the resulting product of the electron transfer redox that occur
when the monovalent silver ions are oxidized and the
trivalent ions are reduced in the crystal. The binding/
chelation effect occurs at active sites of the AIDS virus,
pathogens and ISM. Because of the extremely minute size of
a single molecule of this crystal, several million of these
devices may be employed in concert to destroy a virus
colony to purge a life support system of ISM and pathogens
with the consumption of only parts per trillion of the crystal
devices. Thus an optimum of 40 PPM of the devices by
weight of human blood was found to be sufficient to com-
pletely obliterate AIDS. This concentration is slightly over
double of the optimum concentration recommended in appli-
cant’s aforementioned U.S. patent for the destruction of the
human AIDS virus in vitro. Other details concerning the
structure of the crystal and its mechanism against pathogens,
the AIDS virus and ISM would analogously hold here, and
have already been further elucidated in said patent.

The actual destruction of pathogens, ISM and the AIDS
virus is effectuated by injection of a suspension of these
devices in distilled or deionized water with a non-reacting
electrolyte directly. ic. intravenously, into the bloodstream.
A single injection is all that is required under these condi-
tions. Accordingly, humans injected in this manner, upon

Page 3

5,676,977

3

being inspected after three weeks or more had elapsed and.
compared with similar humans that had been given
placebos, were completely cured of AIDS. The control
group still manifested AIDS. Accordingly, the tetrasilver
tetroxide device performed in concert with and in full
conformity with the ultimate objects of this invention.
Furthermore, three out of four wasting syndrome terminal
patients and four out of the five candidiasis terminal patients
were still alive in 1995 after a year and a half had elapsed
from their initial injection. By that time all the AIDS patients
had been released from the clinic and allowed to return
home.

Other objects and features of the present invention shall
become apparent to those skilled in the art when the present
invention is considered in view of the accompanying
examples. It should, of course, be recognized that the
accompanying examples illustrate preferred embodiments of
the present invention and are not intended as a means of
defining the limits and scope of the present invention.

EXAMPLE 1

Five patients afflicted with AIDS of the candidiasis etio-
logical category were segregated for Tetrasil treatment. The
rationale for selecting them was based on facts presented in
an article by Peter H. Duesberg and Brian J. Ellison entitled
“Is The AIDS Virus A Science Fiction?” (Policy Review,
Summer 1990 pp. 40-51). Only the factual presentations of
the article were utilized and the hypothesis of the authors
was ignored. The facts presented in the article related to the
method of selecting AIDS patients based on the five afore-
mentioned etiological subgroups targeted by the CDC, and
the evidence presented, that there is AIDS without HIV as
well as with it so that an anti-viral agent in most instances
will not necessarily restore the immunity system.

Evaluations with Tetrasil were conducted on AIDS
patients at Lucha Contra el Sida, Comayaguela, Honduras.
The patients two weeks prior to inoculation were removed
from their AZT, AIDS therapy. Tetrasil was administered at
approximately 40 PPM of blood volume per patient as a
suspension in a proprietary buffer solution (pH=6.5), sup-
plied by Holipharm Corporation.

The results of evaluations with candidiasis are tabulated
in Table I under its disease category. All patients evaluated
were terminal. Some, however, were in moderate (m) con-
dition and others in poor (p) as designated in the Table. The
Tand F designations refer to initial and final values as shown.
WEC indicates white cell blood count. The H column,
following CD 8, indicates whether hepatomegaly occurred.

20

45

4

This was an unfortunate consequence of the treatment which
resulted in enlarged livers in all patients except the second
one. Despite hepatomegaly, there was no interference with
liver function.

The onset of hepatomegaly was not spontaneous and
varied from patient to patient, being in the range of 4-16
days.

It should also be noted that shortly after injection of
Tetrasil there were indications of fever (symbolized by T in
the Ag,O, column), sometimes accompanied by fatigue (F).
The body temperature was invariably 38.5° C. (101.3° EF).
This was indicative of restoration of the immune response of
the body, since normally the body will destroy pathogens
when the immune system is functional by raising the tem-
perature. The patient who died; first responded favorably to
Diflucan, which previously gave no response. He was cured
of his candidiasis, but unfortunately succumbed to his pre-
vious body damage. All the other candidiasis syndrome
people who previously did not respond to the indicated
medications subsequently responded after the Tetrasil treat-
ment. Further evidence of the recovery of the AIDS patients
manifested itself 30 days after the initial injection when
white blood cell counts were taken. They are shown in Table
I under the WBC column, which gives the initial and final
WBC. All candidiasis patients showed a dramatic increase in
their white blood cell counts, indicative of the restoration of
their immunity systems.

EXAMPLE 2

The above protocol of Example 1 was repeated with AIDS
patients exhibiting wasting syndrome. The results of their
treatment are tabulated in Table I under the disease category
of said syndrome. It should be noted that two of the four
wasting syndrome patients showed improved white blood
counts. The female patient, whose condition improved from
poor and terminal to be among the living, showed a decrease
in the WBC. However, she showed an increase in body
temperature which was indicative of immune response. The
test results indicate that one cannot rely on a single factor to
indicate the demise of AIDS. The usual HIV marker CD 4
initial and final are irrelevant. ISM suppression appears to be
more critical than the destruction of HIV. AIDS was
suppressed, any permanent damage that had been done to the
Patients in the course of their succumbing to AIDS was not
obviously cured or corrected by said crystal device
treatment, rather said injury persisted and the patient was
improved with respect to AIDS but still suffered from said
permanent injury or impairment previously inflicted.

TABLE I
Response of AIDS Patients to Single 40 PPM Ag,0, Inoculation
Date Weight
DISEASE PATIENT noc. _WBC cD4 DEATH Lbs.
Group Sex Age Media 199 I  F I F CDS H_ 1944 I F  Ag,0,
Candidiasis Mp 28 Diflucan 5/5 1,200 4,200 41 — 221 + @ll a2 6% TT
Fm 33 . SIS 6,000 6,700 554 872 304 — 8 898 OT
Fm 33  Ketaconzl 5/27 2,600 3,850 248 181 951 + 123°«12302~COT
Mp 62 " 62 3,300 3,700 89 27 59+ 105 92 F
Fm 31 Pentamidn 2 2,400 3,050 9 181 65 + 121 118 Pain
Wasting Mm 27 S27 3,600 4,600 39 14 709 + 19 1202=COTT.
Syndrome Mm 28 927 2,750 — 10 — 6 + 719 121 119 TF
Fp 43 527 3,600 2,700 68 26 248 + 101 098 «OF
Mm 19 SAO 3,850 5400 137 36 48 + 103 106. F

Page 4

5,676,977

5

As this invention may be embodied in several forms
without departing from the spirit or essential characteristics
thereof, the present embodiments are therefore illustrative
and not restrictive, since the scope of the invention is defined
by the appended claims rather than by the description
preceding them, and all changes that fall within the metes
and bounds of the claims or that form their functional as well
as conjointly cooperative equivalents, are therefore intended.
to be embraced by these claims.

What is claimed is:

1. A method of treating AIDS-afflicted humans compris-
ing injecting a multitude of tetrasilver tetroxide molecular
crystals into the bloodstream of the human subject.

6

2. A method for increasing white blood cell counts in
AIDS-afflicted humans comprising injecting a multitude of
tetrasilver tetroxide molecular crystals into the bloodstream
of the human subject.

3. Methods of treating AIDS-affilicted humans according
to claims 1-2 where the concentration of said molecular
crystals is approximately 40 PPM of the total blood weight
of the human subject.